Trial Profile
A randomized, double blind, phase III clinical trial, to evaluate the ability of the CV638 attenuated live vaccine candidate Vibrio cholerae 638 O1 El Tor Ogawa strain, to prevent clinical cholera disease caused by the challenge with the virulent strain Vibrio cholerae 3008 . - PVSVCHO
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Oct 2020
Price :
$35
*
At a glance
- Drugs CV 638 (Primary)
- Indications Cholera
- Focus Therapeutic Use
- Acronyms PVSVCHO
- 17 Jan 2017 New trial record